Puma Biotechnology (PBYI) Competitors $3.55 -0.01 (-0.28%) Closing price 07/3/2025 03:21 PM EasternExtended Trading$3.54 0.00 (-0.14%) As of 07/3/2025 04:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PBYI vs. PHAT, URGN, IMTX, DAWN, ABUS, STOK, SION, IOVA, CDXC, and GHRSShould you be buying Puma Biotechnology stock or one of its competitors? The main competitors of Puma Biotechnology include Phathom Pharmaceuticals (PHAT), Urogen Pharma (URGN), Immatics (IMTX), Day One Biopharmaceuticals (DAWN), Arbutus Biopharma (ABUS), Stoke Therapeutics (STOK), Sionna Therapeutics (SION), Iovance Biotherapeutics (IOVA), ChromaDex (CDXC), and GH Research (GHRS). These companies are all part of the "pharmaceutical products" industry. Puma Biotechnology vs. Its Competitors Phathom Pharmaceuticals Urogen Pharma Immatics Day One Biopharmaceuticals Arbutus Biopharma Stoke Therapeutics Sionna Therapeutics Iovance Biotherapeutics ChromaDex GH Research Phathom Pharmaceuticals (NASDAQ:PHAT) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations. Which has better valuation & earnings, PHAT or PBYI? Puma Biotechnology has higher revenue and earnings than Phathom Pharmaceuticals. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPhathom Pharmaceuticals$55.25M11.07-$334.33M-$5.24-1.67Puma Biotechnology$230.50M0.76$30.28M$0.774.61 Does the media prefer PHAT or PBYI? In the previous week, Puma Biotechnology had 1 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 2 mentions for Puma Biotechnology and 1 mentions for Phathom Pharmaceuticals. Puma Biotechnology's average media sentiment score of 0.50 beat Phathom Pharmaceuticals' score of 0.00 indicating that Puma Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phathom Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Puma Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is PHAT or PBYI more profitable? Puma Biotechnology has a net margin of 16.37% compared to Phathom Pharmaceuticals' net margin of -422.42%. Puma Biotechnology's return on equity of 49.35% beat Phathom Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Phathom Pharmaceuticals-422.42% N/A -90.11% Puma Biotechnology 16.37%49.35%18.25% Do analysts prefer PHAT or PBYI? Phathom Pharmaceuticals presently has a consensus target price of $17.50, indicating a potential upside of 99.66%. Puma Biotechnology has a consensus target price of $7.00, indicating a potential upside of 97.18%. Given Phathom Pharmaceuticals' higher probable upside, equities analysts clearly believe Phathom Pharmaceuticals is more favorable than Puma Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Phathom Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.00Puma Biotechnology 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders believe in PHAT or PBYI? 99.0% of Phathom Pharmaceuticals shares are held by institutional investors. Comparatively, 61.3% of Puma Biotechnology shares are held by institutional investors. 23.0% of Phathom Pharmaceuticals shares are held by insiders. Comparatively, 23.3% of Puma Biotechnology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has more volatility & risk, PHAT or PBYI? Phathom Pharmaceuticals has a beta of 0.45, meaning that its share price is 55% less volatile than the S&P 500. Comparatively, Puma Biotechnology has a beta of 1.29, meaning that its share price is 29% more volatile than the S&P 500. SummaryPuma Biotechnology beats Phathom Pharmaceuticals on 11 of the 16 factors compared between the two stocks. Get Puma Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for PBYI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PBYI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PBYI vs. The Competition Export to ExcelMetricPuma BiotechnologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$177.68M$2.91B$5.54B$9.05BDividend YieldN/A2.44%5.24%4.02%P/E Ratio4.6121.5627.4320.23Price / Sales0.76281.76416.89118.64Price / Cash4.2042.7336.8958.07Price / Book1.897.518.035.67Net Income$30.28M-$55.05M$3.18B$249.13M7 Day Performance6.61%4.61%2.89%3.28%1 Month Performance-2.74%4.72%3.70%5.56%1 Year Performance20.34%5.92%36.02%21.12% Puma Biotechnology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PBYIPuma Biotechnology4.1894 of 5 stars$3.55-0.3%$7.00+97.2%+17.5%$177.68M$230.50M4.61200PHATPhathom Pharmaceuticals3.5965 of 5 stars$9.47-9.1%$17.50+84.8%-14.5%$661.14M$81.86M-1.81110High Trading VolumeURGNUrogen Pharma4.4706 of 5 stars$14.30-2.4%$32.86+129.8%-10.1%$659.37M$90.40M-4.50200High Trading VolumeIMTXImmatics2.4597 of 5 stars$5.42-3.4%$14.67+170.6%-52.3%$658.80M$168.65M-31.88260DAWNDay One Biopharmaceuticals1.7343 of 5 stars$6.48+2.5%$30.57+371.8%-49.6%$656.81M$131.16M-9.1360Upcoming EarningsABUSArbutus Biopharma1.6269 of 5 stars$3.41-0.6%$5.50+61.3%+2.4%$653.12M$6.17M-8.3290STOKStoke Therapeutics4.0357 of 5 stars$11.59+0.1%$23.20+100.2%-9.4%$632.78M$190.91M14.67100Analyst ForecastSIONSionna TherapeuticsN/A$14.10-2.7%$38.50+173.0%N/A$622.15MN/A0.0035Positive NewsInsider TradeIOVAIovance Biotherapeutics4.71 of 5 stars$1.85-6.6%$12.22+560.7%-76.3%$617.77M$164.07M-1.49500CDXCChromaDex3.2254 of 5 starsN/A$9.03+∞N/A$611.50M$99.60M787.29120GHRSGH Research2.0695 of 5 stars$11.68-5.1%$32.00+174.0%+23.7%$607.71MN/A-14.7810Analyst Upgrade Related Companies and Tools Related Companies Phathom Pharmaceuticals Competitors Urogen Pharma Competitors Immatics Competitors Day One Biopharmaceuticals Competitors Arbutus Biopharma Competitors Stoke Therapeutics Competitors Sionna Therapeutics Competitors Iovance Biotherapeutics Competitors ChromaDex Competitors GH Research Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PBYI) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Puma Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Puma Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PBYI Stock Alerts